{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T20:00:44Z","timestamp":1759694444631},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,5,23]],"date-time":"2016-05-23T00:00:00Z","timestamp":1463961600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00280-016-3053-3","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T05:14:54Z","timestamp":1464066894000},"page":"217-218","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Developing more effective, non-neurotoxic, methotrexate-based therapy in infants with brain tumors"],"prefix":"10.1007","volume":"78","author":[{"given":"Ian J.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,5,23]]},"reference":[{"key":"3053_CR1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00280-016-3008-8","volume":"77","author":"ML Lucchesi","year":"2016","unstructured":"Lucchesi ML, Guidi M, Fonte C, Farina S, Fiorini P, Favre C, de Martino M, Sardi I (2016) Pharmacokinetics of high-dose methotrexate in infants less than 12\u00a0months treated for aggressive brain tumors. Cancer Chemother Pharmacol 77:857\u2013864","journal-title":"Cancer Chemother Pharmacol"},{"key":"3053_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1200\/JCO.1985.3.1.19","volume":"3","author":"M Morse","year":"1985","unstructured":"Morse M, Savitch J, Balis F, Miser J, Feusner J, Reaman G, Poplack D, Bleyer A (1985) Altered central nervous system pharmacology of methotrexate in childhood leukemia; another sign of meningeal relapse. J Clin Oncol 3:19\u201324","journal-title":"J Clin Oncol"},{"key":"3053_CR3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1471-4159.1978.tb07059.x","volume":"30","author":"RJ Pollock","year":"1978","unstructured":"Pollock RJ, Kaufman S (1978) Dihydrofolate is present in the brain. Neurochem 30:253\u2013256","journal-title":"Neurochem"},{"key":"3053_CR4","first-page":"1982","volume":"37","author":"DG Poplack","year":"1977","unstructured":"Poplack DG, Bleyer WA, Wood JH, Kostolich M, Savitch JL, Ommaya AK (1977) A primate model to study pharmacokinetics in the central nervous system. Cancer Res 37:1982\u20131985","journal-title":"Cancer Res"},{"key":"3053_CR5","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1182\/blood.V97.11.3370","volume":"97","author":"C Patte","year":"2001","unstructured":"Patte C, Auperin A, Michon J, Behrendt H, Leverger G, Frappaz D, Ludz P, Coze C, Perel Y, Raphael M, Terrier M et al (2001) THE SOCIETE francaise d\u2019\u00d3ncologie pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370\u20133379","journal-title":"Blood"},{"key":"3053_CR6","first-page":"345","volume":"38","author":"FM Sirotnak","year":"1978","unstructured":"Sirotnak FM, Moccio DM, Dorick DM (1978) Optimization of high-dose methotrexate with leucovorin rescue therapy in the\u00a0L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res 38:345\u2013353","journal-title":"Cancer Res"},{"key":"3053_CR7","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.mehy.2006.04.074","volume":"68","author":"IJ Cohen","year":"2007","unstructured":"Cohen IJ (2007) Prevention of high-dose\u2014methorexate neurotoxicity by adequate folinic acid rescue is possible even after central nervous system irradiation. Med Hypotheses 68:1147\u20131153","journal-title":"Med Hypotheses"},{"key":"3053_CR8","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.mehy.2013.08.027","volume":"81","author":"IJ Cohen","year":"2013","unstructured":"Cohen IJ (2013) Challenging the clinical relevance of folinic acid over rescue after high dose MTX. Med Hypotheses 81:942\u2013947","journal-title":"Med Hypotheses"},{"key":"3053_CR9","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0277-5379(91)90269-J","volume":"27","author":"JD Borsi","year":"1991","unstructured":"Borsi JD, Wesenberg F, Stokland T, Moe PJ (1991) How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukemia. Eur J Cancer 27:1006\u20131009","journal-title":"Eur J Cancer"},{"key":"3053_CR10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MPH.0b013e31828c2da1","volume":"35","author":"E Bonda-Shkedi","year":"2013","unstructured":"Bonda-Shkedi E, Weyl Ben Harush M, Kaplinsky C, Ash S, Goshen Y, Yaniv I, Cohen IJ (2013) The correlation between dose of folinic acid and neurotoxicity in children and adolescents treated with osteosarcoma with high-dose methotrexate (HDMTX): a neuropsychological and psychosocial study. J Pediatr Hematol Oncol 35:271\u2013275","journal-title":"J Pediatr Hematol Oncol"},{"key":"3053_CR11","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1200\/JCO.2006.05.9055","volume":"24","author":"BJ Spiegler","year":"2006","unstructured":"Spiegler BJ, Kimberly K, Maze R, Greenberg ML, Weitzman S, Hitzler JK, Nathan PC (2006) Comparison of long term neurocognitive outcome in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high dose intravenous methotrexate. J Clin Oncol 24:3858\u20133864","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3053-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3053-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3053-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:07:42Z","timestamp":1559038062000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3053-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,23]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["3053"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3053-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,23]]}}}